- The first participant has been enrolled in a 100-subject, open-label, single-arm Phase 1 clinical trial evaluating Dynavax's (NASDAQ:DVAX) HEPLISAV-B [Hepatitis B Vaccine, Recombinant (Adjuvanted)] in adults with end-stage renal disease who are initiating or are undergoing hemodialysis.
- The primary endpoints are safety and immunogenicity at week 20 as measured by seroprotection rate.
- The estimated primary completion date is December.
Enrollment underway in study of Dynavax's HEPLISAV-B in renal disease patients
Recommended For You
About DVAX Stock
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
DVAX | - | - |
Dynavax Technologies Corporation |